|

UCAR T-cell Clinical Trials

4 actively recruiting trials

No change since May 2026

Pipeline

Early 1: 2Phase 1: 2

Top Sponsors

  • The Children's Hospital of Zhejiang University School of Medicine2
  • Tianjin Huanhu Hospital1
  • Institute of Hematology & Blood Diseases Hospital, China1

Indications

  • Systemic Sclerosis (SSc)3
  • Lupus3
  • Multiple Sclerosis3
  • ANCA Associated Systemic Vasculitis2
  • Multi-Drug Resistant Nephrotic Syndrome2

Other4 trials

Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease
Early 1
CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease
Phase 1
CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases
Phase 1
Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/B Cell Maturation Antigen （CD19/BCMA） in Patients With r/r Neurological Autoimmune Diseases
Early 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.